ITOS
Income statement / Annual
Last year (2024), iTeos Therapeutics, Inc.'s total revenue was $35.00 M,
an increase of 177.89% from the previous year.
In 2024, iTeos Therapeutics, Inc.'s net income was -$134.41 M.
See iTeos Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$35.00 M |
$12.60 M |
$267.63 M |
$344.78 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.24 M
|
$898.00 K
|
$813.00 K
|
$615.00 K
|
$535.00 K
|
$611.00 K
|
$505.00 K
|
| Gross Profit |
$33.76 M
|
$11.70 M
|
$266.82 M
|
$344.16 M
|
-$535.00 K
|
-$611.00 K
|
-$505.00 K
|
| Gross Profit Ratio |
0.96
|
0.93
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$145.45 M
|
$113.30 M
|
$97.36 M
|
$59.37 M
|
$29.90 M
|
$19.21 M
|
$17.19 M
|
| General & Administrative Expenses |
$49.08 M
|
$50.40 M
|
$43.95 M
|
$40.51 M
|
$15.34 M
|
$8.84 M
|
$4.31 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.08 M
|
$50.40 M
|
$43.95 M
|
$40.51 M
|
$15.34 M
|
$8.84 M
|
$4.31 M
|
| Other Expenses |
-$1.24 M
|
-$898.00 K
|
-$813.00 K
|
-$615.00 K
|
-$535.00 K
|
-$4.78 M
|
-$163.00 K
|
| Operating Expenses |
$193.29 M
|
$162.80 M
|
$140.49 M
|
$99.26 M
|
$44.71 M
|
$23.27 M
|
$17.82 M
|
| Cost And Expenses |
$194.53 M
|
$163.70 M
|
$141.31 M
|
$99.87 M
|
$45.24 M
|
$23.27 M
|
$17.82 M
|
| Interest Income |
$30.87 M
|
$31.77 M
|
$11.36 M
|
$78.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$66.00 K
|
| Depreciation & Amortization |
$1.24 M
|
$898.00 K
|
$813.00 K
|
$615.00 K
|
$535.00 K
|
$611.00 K
|
$505.00 K
|
| EBITDA |
-$121.82 M |
-$111.66 M |
$148.38 M |
$257.08 M |
-$37.84 M |
-$22.51 M |
-$17.48 M |
| EBITDA Ratio |
-3.48
|
-8.87
|
0.55
|
0.75
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.56
|
-12
|
0.47
|
0.71
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$39.19 M
|
$42.07 M
|
$22.41 M
|
$11.56 M
|
$7.15 M
|
$5.71 M
|
$3.46 M
|
| Income Before Tax |
-$120.34 M
|
-$109.03 M
|
$148.74 M
|
$256.46 M
|
-$38.09 M
|
-$22.34 M
|
-$18.05 M
|
| Income Before Tax Ratio |
-3.44
|
-8.66
|
0.56
|
0.74
|
0
|
0
|
0
|
| Income Tax Expense |
$14.07 M
|
$3.61 M
|
$52.08 M
|
$41.94 M
|
-$57.00 K
|
$119.00 K
|
$11.00 K
|
| Net Income |
-$134.41 M
|
-$112.64 M
|
$96.65 M
|
$214.52 M
|
-$38.03 M
|
-$22.45 M
|
-$18.06 M
|
| Net Income Ratio |
-3.84
|
-8.94
|
0.36
|
0.62
|
0
|
0
|
0
|
| EPS |
-3.32 |
-3.15 |
2.72 |
6.1 |
-1.24 |
-2.27 |
-2.4 |
| EPS Diluted |
-3.32 |
-3.15 |
2.56 |
5.68 |
-1.24 |
-2.27 |
-2.4 |
| Weighted Average Shares Out |
$40.47 M
|
$35.76 M
|
$35.55 M
|
$35.18 M
|
$35.04 M
|
$9.91 M
|
$7.51 M
|
| Weighted Average Shares Out Diluted |
$40.47 M
|
$35.76 M
|
$37.77 M
|
$37.77 M
|
$35.04 M
|
$9.91 M
|
$7.51 M
|
| Link |
|
|
|
|
|
|
|
